Related Experiment Video
Updated: Aug 16, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
[Neuroendocrine tumours treated with mIBG and radiolabeled peptides]
F Giammarile1, F Borson-Chazot
1Département de Médecine Nucléaire, Centre Léon-Bérard, 28, rue Laennec, 69373 Lyon cedex 08, France. giammari@lyon.fnclcc.fr
Abstract:
Neuroendocrine tumours are a heterogeneous group, characterized by good prognosis, but important disparities of the evolutionary potential. In the aggressive forms, the therapeutic strategies are limited. The metabolic or systemic radiotherapy, using radiolabelled peptides, which can act at the same time on the primary tumour and its metastases, constitutes a tempting therapeutic alternative, currently in evolution. The preliminary results are encouraging; the prospects are related to the development of new radiopharmaceuticals, with the use of other peptide analogues whose applications will overflow the framework of the neuroendocrine tumours.
Insights
Neuroendocrine tumors (NETs) are diverse, with aggressive forms having limited treatment options. Radiolabeled peptide receptor radionuclide therapy is an evolving, promising alternative for treating NETs and their metastases.
Area of Science:
- Oncology
- Nuclear Medicine
- Endocrinology
Context:
- Neuroendocrine tumors (NETs) present a significant clinical challenge due to their heterogeneity and variable prognosis.
- Aggressive NETs often have limited therapeutic strategies, necessitating novel treatment approaches.
- Peptide receptor radionuclide therapy (PRRT) is an emerging treatment modality for NETs.
Purpose:
- To explore the potential of radiolabeled peptide therapy as a treatment for neuroendocrine tumors.
- To evaluate the current status and future prospects of systemic radiotherapy using radiolabeled peptides for NETs.
- To discuss the development of new radiopharmaceuticals and peptide analogues for NET treatment.
Summary:
- Neuroendocrine tumors are a heterogeneous group with variable evolutionary potential, posing treatment challenges in aggressive forms.
- Systemic radiotherapy with radiolabeled peptides offers a therapeutic alternative, targeting both primary tumors and metastases.
- Preliminary results for this approach are encouraging, with ongoing development of novel radiopharmaceuticals and peptide analogues.
Impact:
- Radiolabeled peptide therapy shows promise as a treatment for neuroendocrine tumors, potentially improving outcomes.
- The development of new radiopharmaceuticals could expand therapeutic options beyond neuroendocrine tumors.
- This evolving field offers hope for more effective management of aggressive neuroendocrine neoplasms.
